Saturday 17 October 2026
Export TCRT’s income statement to Excel — free account
Alaunos Therapeutics, Inc.
TCRT Healthcare Biotechnology
Alaunos Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $5,000.00, down 50.0% from fiscal 2024. In the quarter to June 2026, revenue grew 200.0%, EPS grew 34.9% and free cash flow grew 57.2%, each against the same quarter a year earlier.
2.63
0.45
+20.64%
Follow TCRT
Alaunos Therapeutics, Inc. (TCRT) P/E ratio
Alaunos Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Mar 2025 | 0.0× | — |
| Dec 2024 | 0.0× | — |
| Jun 2024 | 0.0× | — |
| 19 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TRAW Traws Pharma, Inc. compare | n/m |
| SYBX Synlogic, Inc. compare | n/m |
| ENVB Enveric Biosciences, Inc. compare | n/m |
| EVGN Evogene Ltd. compare | n/m |
| TCRT Alaunos Therapeutics, Inc. | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| ALZN Alzamend Neuro, Inc. compare | n/m |
| ACXP Acurx Pharmaceuticals, Inc. compare | n/m |
| LEXX Lexaria Bioscience Corp. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)